144 related articles for article (PubMed ID: 37309823)
21. Differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma on gadoxetic acid-enhanced liver MR imaging.
Kim R; Lee JM; Shin CI; Lee ES; Yoon JH; Joo I; Kim SH; Hwang I; Han JK; Choi BI
Eur Radiol; 2016 Jun; 26(6):1808-17. PubMed ID: 26373763
[TBL] [Abstract][Full Text] [Related]
22. The Application Value of MRI T2
Huang F; Liu X; Liu P; Xu D; Li Z; Lin H; Xie A
Comput Math Methods Med; 2022; 2022():7099476. PubMed ID: 36203532
[TBL] [Abstract][Full Text] [Related]
23. Update on the association of hepatitis B with intrahepatic cholangiocarcinoma: Is there new evidence?
Fragkou N; Sideras L; Panas P; Emmanouilides C; Sinakos E
World J Gastroenterol; 2021 Jul; 27(27):4252-4275. PubMed ID: 34366604
[TBL] [Abstract][Full Text] [Related]
24. Distinguishing intrahepatic mass-forming biliary carcinomas from hepatocellular carcinoma by computed tomography and magnetic resonance imaging using the Bayesian method: a bi-center study.
Ichikawa S; Isoda H; Shimizu T; Tamada D; Taura K; Togashi K; Onishi H; Motosugi U
Eur Radiol; 2020 Nov; 30(11):5992-6002. PubMed ID: 32500195
[TBL] [Abstract][Full Text] [Related]
25. Added value of ancillary imaging features for differentiating scirrhous hepatocellular carcinoma from intrahepatic cholangiocarcinoma on gadoxetic acid-enhanced MR imaging.
Choi SY; Kim YK; Min JH; Kang TW; Jeong WK; Ahn S; Won H
Eur Radiol; 2018 Jun; 28(6):2549-2560. PubMed ID: 29335868
[TBL] [Abstract][Full Text] [Related]
26. Contrast-enhanced MRI could predict response of systemic therapy in advanced intrahepatic cholangiocarcinoma.
Sheng R; Huang X; Jin K; Gao S; Zeng M; Wu D; Shi G
Eur Radiol; 2022 Aug; 32(8):5156-5165. PubMed ID: 35298678
[TBL] [Abstract][Full Text] [Related]
27. Mass-forming intrahepatic cholangiocarcinoma: Can diffusion-weighted imaging predict microvascular invasion?
Zhou Y; Wang X; Xu C; Zhou G; Liu X; Gao S; Xu P
J Magn Reson Imaging; 2019 Jul; 50(1):315-324. PubMed ID: 30444023
[TBL] [Abstract][Full Text] [Related]
28. Role of Intravoxel Incoherent Motion in Discriminating Hepatitis B Virus-Related Intrahepatic Mass-Forming Cholangiocarcinoma from Hepatocellular Carcinoma Based on Liver Imaging Reporting and Data System v2018.
Shao S; Shan Q; Zheng N; Wang B; Wang J
Cancer Biother Radiopharm; 2019 Oct; 34(8):511-518. PubMed ID: 31314589
[No Abstract] [Full Text] [Related]
29. Added-value of ancillary imaging features for differentiating hepatocellular carcinoma from intrahepatic mass-forming cholangiocarcinoma on Gd-BOPTA-enhanced MRI in LI-RADS M.
Zheng W; Huang H; She D; Xiong M; Chen X; Lin X; Cao D
Abdom Radiol (NY); 2022 Mar; 47(3):957-968. PubMed ID: 34964069
[TBL] [Abstract][Full Text] [Related]
30. Preoperative Diagnosis of Dual-Phenotype Hepatocellular Carcinoma Using Enhanced MRI Radiomics Models.
Wu Q; Yu YX; Zhang T; Zhu WJ; Fan YF; Wang XM; Hu CH
J Magn Reson Imaging; 2023 Apr; 57(4):1185-1196. PubMed ID: 36190656
[TBL] [Abstract][Full Text] [Related]
31. Combined hepatocellular-cholangiocarcinoma: which preoperative clinical data and conventional MRI characteristics have value for the prediction of microvascular invasion and clinical significance?
Wang X; Wang W; Ma X; Lu X; Li S; Zeng M; Xu K; Yang C
Eur Radiol; 2020 Oct; 30(10):5337-5347. PubMed ID: 32385649
[TBL] [Abstract][Full Text] [Related]
32. Component with abundant immune-related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis.
Yagi N; Suzuki T; Mizuno S; Kojima M; Kudo M; Sugimoto M; Kobayashi S; Gotohda N; Ishii G; Nakatsura T
Cancer Sci; 2022 May; 113(5):1564-1574. PubMed ID: 35226764
[TBL] [Abstract][Full Text] [Related]
33. MRI of small intrahepatic mass-forming cholangiocarcinoma and atypical small hepatocellular carcinoma (≤3 cm) with cirrhosis and chronic viral hepatitis: a comparative study.
Sheng RF; Zeng MS; Rao SX; Ji Y; Chen LL
Clin Imaging; 2014; 38(3):265-72. PubMed ID: 24559750
[TBL] [Abstract][Full Text] [Related]
34. Imaging features of combined hepatocellular and cholangiocarcinoma compared with those of hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in a Chinese population.
Wang Y; Yang Q; Li S; Luo R; Mao S; Shen J
Clin Radiol; 2019 May; 74(5):407.e1-407.e10. PubMed ID: 30799097
[TBL] [Abstract][Full Text] [Related]
35. Implications of ultrasound-based deep learning model for preoperatively differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Chen J; Zhang W; Bao J; Wang K; Zhao Q; Zhu Y; Chen Y
Abdom Radiol (NY); 2024 Jan; 49(1):93-102. PubMed ID: 37999743
[TBL] [Abstract][Full Text] [Related]
36. Tumor ratio of unsaturated to saturated sulfatide species is associated with disease-free survival in intrahepatic cholangiocarcinoma.
Huizing L; Chen L; Roeth AA; Heij LR; Flinders B; Bouwense SAW; Balluff B; Neumann UP; Heeren RMA; Olde Damink SWM; Vreeken RJ; Schaap FG
Cell Oncol (Dordr); 2023 Jun; 46(3):629-642. PubMed ID: 36630049
[TBL] [Abstract][Full Text] [Related]
37. Optimizing CT and MRI criteria for differentiating intrahepatic mass-forming cholangiocarcinoma and hepatocellular carcinoma.
Wu H; Liang Y; Wang Z; Tan C; Yang R; Wei X; Jiang X
Acta Radiol; 2023 Mar; 64(3):926-935. PubMed ID: 35898164
[TBL] [Abstract][Full Text] [Related]
38. Clinical Significance of Acylphosphatase 1 Expression in Combined HCC-iCCA, HCC, and iCCA.
Sakano Y; Noda T; Kobayashi S; Kitagawa A; Iwagami Y; Yamada D; Tomimaru Y; Akita H; Gotoh K; Asaoka T; Tanemura M; Umeshita K; Mimori K; Doki Y; Eguchi H
Dig Dis Sci; 2022 Aug; 67(8):3817-3830. PubMed ID: 34626299
[TBL] [Abstract][Full Text] [Related]
39. Differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in high-risk patients matched to MR field strength: diagnostic performance of LI-RADS version 2018.
Zou X; Luo Y; Morelli JN; Hu X; Shen Y; Hu D
Abdom Radiol (NY); 2021 Jul; 46(7):3168-3178. PubMed ID: 33660040
[TBL] [Abstract][Full Text] [Related]
40. How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI?
Lee HS; Kim MJ; An C
Eur Radiol; 2019 May; 29(5):2408-2416. PubMed ID: 30552477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
